KPV peptide can't penetrate skin on its own, but combining microneedle pre-treatment with iontophoresis (mild electrical current) boosts delivery 35-fold, potentially enabling needle-free anti-inflammatory treatment.
35-fold delivery boost with combined approachMicroneedles plus iontophoresis increased KPV skin permeation 35 times compared to microneedles alone — from undetectable passive diffusion to therapeutically relevant levels
What the researchers found
KPV peptide cannot cross the skin by passive diffusion — levels were undetectable. But combining two enhancement technologies dramatically changed this: microneedles alone increased permeation to 4.4 μg/cm²/h, iontophoresis (electrical current) alone was 8-fold better than microneedles, and combining both technologies boosted delivery 35-fold over microneedles alone.
Skin retention also improved dramatically — 10-fold higher KPV was retained in the skin when using iontophoresis or the combination approach. Confocal imaging confirmed the peptide penetrated beyond 100 μm depth, reaching the lower epidermis.
Why it matters
KPV is a potent anti-inflammatory peptide, but like most peptides, it can't cross the skin barrier on its own — making injection the only option. This study demonstrates a path toward needle-free KPV delivery through the skin using microneedles and electrical current. If this approach translates to clinical use, it could make KPV accessible as a topical anti-inflammatory treatment.
The numbers in context
Passive diffusion: undetectable · microneedles: 4.4 μg/cm²/h · iontophoresis: 8× microneedles · combination: 35× microneedles · skin retention: 10× passive · penetration depth: >100 μm
How the study worked
In vitro permeation study using dermatomed (thickness-controlled) human skin. Researchers tested four delivery approaches: passive diffusion, microneedle pre-treatment alone, iontophoresis alone, and microneedles plus iontophoresis combined. They varied current strength, KPV concentration, and duration. Permeation and skin retention were quantified, and confocal microscopy with fluorescently-labeled KPV was used to visualize penetration depth.
Who was studied
In vitro study using dermatomed human skin samples (no living subjects)
What this study cannot tell us
This is an in vitro study using excised human skin — it does not account for blood flow, immune responses, or systemic absorption that would occur in living tissue. No animal or human in vivo testing was performed. The anti-inflammatory effect of the delivered KPV was not measured — only the physical delivery was assessed. Long-term skin safety of repeated iontophoresis and microneedling was not evaluated.
How to read the evidence
This is a well-designed in vitro study using human skin, but it's purely a drug delivery proof-of-concept. No therapeutic effects were measured, and no in vivo testing was performed. The evidence is early-stage — it demonstrates feasibility but not clinical utility.
When this study was published
Published in 2017. Transdermal peptide delivery technology has continued to advance since this study, with microneedle patch technology in particular moving closer to commercial products. The fundamental delivery data remains relevant.
The bigger picture
Peptide drug delivery is one of the biggest challenges in pharmaceutical science — most peptides are destroyed in the stomach or can't cross biological barriers. Transdermal delivery is an attractive alternative to injection, especially for locally-acting anti-inflammatory peptides like KPV. This study contributes to a growing body of work showing that combination enhancement strategies (microneedles + iontophoresis) can overcome the skin barrier for peptide delivery.
Questions still open
- Does the KPV delivered through the skin retain its anti-inflammatory activity and produce therapeutic effects in living tissue?
- Could this delivery approach be developed into a practical patient-friendly device for KPV treatment?
- How does repeated microneedling and iontophoresis affect skin health over time?
Common questions
What is iontophoresis and does it hurt?
Why can't KPV just be applied as a cream?
Read the original research
Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.
Journal of pharmaceutical sciences, 106(7), 1814-1820
Citation
Pawar, Kasturi; Kolli, Chandra S; Rangari, Vijaya K; Babu, R Jayachandra. (2017). Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.. Journal of pharmaceutical sciences, 106(7), 1814-1820. https://doi.org/10.1016/j.xphs.2017.03.017